Alpine Immune Sciences, Inc. (ALPN)

64,60 0,00 (0,00%) Börsenschluss: 04:00PM EDT

Alpine Immune Sciences, Inc.

188 East Blaine Street
Suite 200
Seattle, WA 98102
United States
206 788 4545
https://www.alpineimmunesciences.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 142

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Mitchell H. Gold M.D.	Executive Chairman & CEO	1,02M	N/A	1968
Dr. Stanford Peng M.D., Ph.D.	President and Head of Research & Development	940,1k	N/A	1971
Mr. Paul Rickey	Senior VP, CFO, Treasurer & Secretary	691,1k	N/A	1979
Mr. Ulrich Martin Fuhs	VP of Finance & Chief Accounting Officer	N/A	N/A	1968
Ms. M. Christina Yi	Chief Technology Officer	N/A	N/A	1976
Ms. Michelle Greenblatt	Director of Investor Relations & Corporate Communications	N/A	N/A	N/A
Dr. Remy Durand Ph.D.	Chief Business Officer	N/A	N/A	1986
Dr. Andrew Seth Sandler M.D.	Chief Medical Officer	N/A	N/A	1965

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

Corporate Governance

Alpine Immune Sciences, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 8. Die grundlegenden Scores sind Audit: 8, Vorstand: 8, Shareholderrechte: 8, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.